Castle Biosciences Inc.

11/04/2025 | Press release | Distributed by Public on 11/04/2025 19:38

Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Oelschlager Kristen M
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [CSTL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Operating Officer
(Last) (First) (Middle)
C/O CASTLE BIOSCIENCES, INC., 505 S FRIENDSWOOD DRIVE, SUITE 401
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
(Street)
FRIENDSWOOD, TX 77546
4. If Amendment, Date Original Filed (Month/Day/Year)
08/29/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 S 18,007 D $21.69(1) 100,937(2) I The Fritz Shorter Trust(3)
Common Stock 52,924(2) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Oelschlager Kristen M
C/O CASTLE BIOSCIENCES, INC.
505 S FRIENDSWOOD DRIVE, SUITE 401
FRIENDSWOOD, TX 77546
Chief Operating Officer

Signatures

/s/ Frank Stokes, Attorney-in-fact 11/04/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This transaction was executed in multiple trades at prices ranging from $21.24 to $21.94, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
(2) On August 29, 2025, the Reporting Person filed a Form 4 which inadvertently reported that shares were sold by the Reporting Person directly. In fact, as reported in this amendment, the shares were sold by the Fritz Shorter Trust (the "Trust"). The original Form 4 also mistakenly indicated the wrong number of shares held by the Reporting Person directly and indirectly through the Trust. In fact, following this sale, the Reporting Person held 52,924 shares of common stock directly and 100,937 shares of common stock indirectly through the Trust. In addition, following a reconciliation of the reporting person's holdings, it was determined that the balance previously reported was understated by 68 shares, and the holdings reported herein have been adjusted accordingly.
(3) On March 19, 2025 and on August 22, 2025, the Reporting Person transferred 96,322 and 22,622 shares to the Trust. The transfer was not a change in beneficial ownership because the Reporting Person and her spouse are the trustees and sole beneficiaries of the Trust, the Trust is revocable and the Reporting Person has voting and investment power over the shares held by the Trust.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Castle Biosciences Inc. published this content on November 04, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 05, 2025 at 01:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]